Autoantibodies in systemic lupus erythematosus: comparison of historical and current assessment of seropositivity
(2011) In Lupus 20(3). p.250-255- Abstract
- Systemic lupus erythematosus (SLE) is characterized by multiple autoantibodies and complement activation. Recent studies have suggested that anti-nuclear antibody (ANA) positivity may disappear over time in some SLE patients. Anti-double-stranded DNA (dsDNA) antibody titers and complement levels may vary with time and immunosuppressive treatment, while the behavior of anti-extractable nuclear antigen (ENA) over time is less well understood. This study sought to determine the correlation between historical autoantibody tests and current testing in patients with SLE. Three hundred and two SLE patients from the ACR Reclassification of SLE (AROSE) database with both historical and current laboratory data were selected for analysis. The... (More)
- Systemic lupus erythematosus (SLE) is characterized by multiple autoantibodies and complement activation. Recent studies have suggested that anti-nuclear antibody (ANA) positivity may disappear over time in some SLE patients. Anti-double-stranded DNA (dsDNA) antibody titers and complement levels may vary with time and immunosuppressive treatment, while the behavior of anti-extractable nuclear antigen (ENA) over time is less well understood. This study sought to determine the correlation between historical autoantibody tests and current testing in patients with SLE. Three hundred and two SLE patients from the ACR Reclassification of SLE (AROSE) database with both historical and current laboratory data were selected for analysis. The historical laboratory data were compared with the current autoantibody tests done at the reference laboratory and tested for agreement using percent agreement and Kappa statistic. Serologic tests included ANA, anti-dsDNA, anti-Smith, anti-ribonucleoprotein (RNP), anti-Ro, anti-La, rheumatoid factor (RF), C3 and C4. Among those historically negative for immunologic markers, a current assessment of the markers by the reference laboratory generally yielded a low percentage of additional positives (3-13%). However, 6/11 (55%) of those historically negative for ANA were positive by the reference laboratory, and the reference laboratory test also identified 20% more patients with anti-RNP and 18% more with RF. Among those historically positive for immunologic markers, the reference laboratory results were generally positive on the same laboratory test (range 57% to 97%). However, among those with a history of low C3 or C4, the current reference laboratory results indicated low C3 or C4 a low percentage of the time (18% and 39%, respectively). ANA positivity remained positive over time, in contrast to previous studies. Anti-Ro, La, RNP, Smith and anti-dsDNA antibodies had substantial agreement over time, while complement had less agreement. This variation could partially be explained by variability of the historical assays, which were done by local laboratories over varying periods of time. Variation in the results for complement, however, is more likely to be explained by response to treatment. These findings deserve consideration in the context of diagnosis and enrolment in clinical trials. Lupus (2011) 20, 250-255. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/1869058
- author
- organization
- publishing date
- 2011
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- ANA, autoantibodies, systemic lupus erythematosus
- in
- Lupus
- volume
- 20
- issue
- 3
- pages
- 250 - 255
- publisher
- SAGE Publications
- external identifiers
-
- wos:000287849000004
- scopus:79958255101
- ISSN
- 0961-2033
- DOI
- 10.1177/0961203310385738
- language
- English
- LU publication?
- yes
- id
- 3a677856-4f6f-4e0d-8516-5688b06c1ef2 (old id 1869058)
- date added to LUP
- 2016-04-01 09:51:08
- date last changed
- 2022-01-25 17:18:44
@article{3a677856-4f6f-4e0d-8516-5688b06c1ef2,
abstract = {{Systemic lupus erythematosus (SLE) is characterized by multiple autoantibodies and complement activation. Recent studies have suggested that anti-nuclear antibody (ANA) positivity may disappear over time in some SLE patients. Anti-double-stranded DNA (dsDNA) antibody titers and complement levels may vary with time and immunosuppressive treatment, while the behavior of anti-extractable nuclear antigen (ENA) over time is less well understood. This study sought to determine the correlation between historical autoantibody tests and current testing in patients with SLE. Three hundred and two SLE patients from the ACR Reclassification of SLE (AROSE) database with both historical and current laboratory data were selected for analysis. The historical laboratory data were compared with the current autoantibody tests done at the reference laboratory and tested for agreement using percent agreement and Kappa statistic. Serologic tests included ANA, anti-dsDNA, anti-Smith, anti-ribonucleoprotein (RNP), anti-Ro, anti-La, rheumatoid factor (RF), C3 and C4. Among those historically negative for immunologic markers, a current assessment of the markers by the reference laboratory generally yielded a low percentage of additional positives (3-13%). However, 6/11 (55%) of those historically negative for ANA were positive by the reference laboratory, and the reference laboratory test also identified 20% more patients with anti-RNP and 18% more with RF. Among those historically positive for immunologic markers, the reference laboratory results were generally positive on the same laboratory test (range 57% to 97%). However, among those with a history of low C3 or C4, the current reference laboratory results indicated low C3 or C4 a low percentage of the time (18% and 39%, respectively). ANA positivity remained positive over time, in contrast to previous studies. Anti-Ro, La, RNP, Smith and anti-dsDNA antibodies had substantial agreement over time, while complement had less agreement. This variation could partially be explained by variability of the historical assays, which were done by local laboratories over varying periods of time. Variation in the results for complement, however, is more likely to be explained by response to treatment. These findings deserve consideration in the context of diagnosis and enrolment in clinical trials. Lupus (2011) 20, 250-255.}},
author = {{Ippolito, A. and Wallace, D. J. and Gladman, D. and Fortin, P. R. and Urowitz, M. and Werth, V. and Costner, M. and Gordon, C. and Alarcon, G. S. and Ramsey-Goldman, R. and Maddison, P. and Clarke, A. and Bernatsky, S. and Manzi, S. and Bae, S-C and Merrill, J. T. and Ginzler, E. and Hanly, J. G. and Nived, Ola and Sturfelt, Gunnar and Sanchez-Guerrero, J. and Bruce, I. and Aranow, C. and Isenberg, D. and Zoma, A. and Magder, L. S. and Buyon, J. and Kalunian, K. and Dooley, M. A. and Steinsson, K. and van Vollenhoven, R. F. and Stoll, T. and Weisman, M. and Petri, M.}},
issn = {{0961-2033}},
keywords = {{ANA; autoantibodies; systemic lupus erythematosus}},
language = {{eng}},
number = {{3}},
pages = {{250--255}},
publisher = {{SAGE Publications}},
series = {{Lupus}},
title = {{Autoantibodies in systemic lupus erythematosus: comparison of historical and current assessment of seropositivity}},
url = {{http://dx.doi.org/10.1177/0961203310385738}},
doi = {{10.1177/0961203310385738}},
volume = {{20}},
year = {{2011}},
}